Preskoči na vsebino

Bolezen srpastih celic (pediatrija)

Anemia Management

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (odpre novo okno)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Vir‎: Lancet Haematol. 2023 ;10(4):e261-71.

Indeksirano‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (odpre novo okno)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (odpre novo okno)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Vir‎: Acta Haematol 1995;94(3):128-34.

Indeksirano‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (odpre novo okno)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (odpre novo okno)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Vir‎: Haematologica 2006;91(8):1076-83.

Indeksirano‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (odpre novo okno)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (odpre novo okno)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Vir‎: J Obstet Gynaecol 2007;27(1):82-3.

Indeksirano‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (odpre novo okno)